2 Wu H, Xu M Q, Liu X Q. Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. Biochim Biophys Acta, 1998, 1387: 422-432
[3]
3 Scallan C D, Liu T, Parker A E, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood, 2003, 102: 3919-3926
[4]
4 Zhang K, Shen X, Wu J, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell, 2006, 124: 587-599
6 Burton M, Nakai H, Colosi P, et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA, 1999, 96: 12725-12730
[7]
7 Chen L X, Zhu F X, Li J, et al. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther, 2007, 15: 1856-1862
[8]
8 Swaroop M, Moussalli M, Pipe S W, et al. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem, 1997, 272: 24121-24124
[9]
9 Arruda V R, Stedman H H, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 2010, 115: 4678-4688
[10]
10 Niemeyer G P, Herzog R W, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liverdirected AAV2-mediated factor IX gene therapy. Blood, 2009, 113: 797-806
[11]
11 Sarkar R, Mucci M, Addya S, et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther, 2006, 17: 427-439
[12]
12 Kaufman R J, Wasley L C, Dorner A J. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cell. J Biol Chem, 1988, 263: 6352-6362
[13]
13 Sabatino D S, Lange A M, Altynova E S, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther, 2011, 19: 442-449
[14]
14 Mah C, Sarkar R, Zolotukhin I, et al. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther, 2003, 14: 143-152
[15]
15 Pipe S W. Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost, 2004, 30: 227-237
[16]
16 Miao H Z, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood, 2004, 103: 3412-3419
[17]
17 Gale A J, Radtke K P, Cunningham M A, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost, 2006, 4: 1315-1322
